EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice

Yoichi Sunagawa iD, Ryosuke Tsukabe, Yudai Irokawa, Masafumi Funamoto, Yuto Suzuki, Miho Yamada, Satoshi Shimizu, Yasufumi Katanasaka iD, Toshihide Hamabe-Horiike iD, Yuto Kawase, Ryuya Naruta, Kana Shimizu und 5 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25042344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yoichi Sunagawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. Hauptthemen laut MEDLINE: Anserine, Cardiomyopathies, Heart Failure, Myocytes, Cardiac. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Nutrition and Food Science Fund of the Japan Society of Nutrition and Food Science, Toyo Institute of Food Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anserine, an imidazole dipeptide, is present in the muscles of birds and fish and has various bioactivities, such as anti-inflammatory and anti-fatigue effects. However, the effect of anserine on the development of heart failure remains unknown. We cultured primary cardiomyocytes with 0.03 mM to 10 mM anserine and stimulated them with phenylephrine for 48 h. Anserine significantly suppressed the phenylephrine-induced increases in cardiomyocyte hypertrophy, ANF and BNP mRNA levels, and histone H3K9 acetylation. An in vitro histone acetyltransferase (HAT) assay showed that anserine directly suppressed p300-HAT activity with an IC50 of 1.87 mM. Subsequently, 8-week-old male C57BL/6J mice were subjected to transverse aortic constriction (TAC) and were randomly assigned to receive daily oral treatment with anserine-containing material, Marine Active® (60 or 200 mg/kg anserine) or vehicle for 8 weeks. Echocardiography revealed that anserine 200 mg/kg significantly prevented the TAC-induced increase in left ventricular posterior wall thickness and the decrease in left ventricular fractional shortening. Moreover, anserine significantly suppressed the TAC-induced acetylation of histone H3K9. These results indicate that anserine suppresses TAC-induced systolic dysfunction, at least in part, by inhibiting p300-HAT activity. Anserine may be used as a pharmacological agent for human heart failure therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnserineCardiomyopathiesHeart FailureMyocytes, Cardiacp300-CBP Transcription FactorsAnimalsHumansMaleMiceAcetylationCardiomegalyEnzyme InhibitorsHistonesMice, Inbred C57BLPhenylephrine

Stichwörter der Autor:innen

anserinecardiomyocyte hypertrophyheart failurehistone acetyltransferase activityp300pressure overload

Substanzen

AnserineEnzyme InhibitorsHistonesPhenylephrinep300-CBP Transcription Factors

Autor:innen und Institutionen

  • Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
  • Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.
  • Shizuoka General Hospital, Shizuoka 420-8527, Japan.
  • Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
  • Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Japan.
  • Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.

ORCID-Profile: Yoichi Sunagawa, Yasufumi Katanasaka, Toshihide Hamabe-Horiike, Kiyoshi Mori, Ryota Hosomi, Maki Komiyama, Tatsuya Morimoto

Förderung

  • Japan Science and Technology Agency
  • Nutrition and Food Science Fund of the Japan Society of Nutrition and Food Science
  • Toyo Institute of Food Technology

Zitieren

APA

Sunagawa, Y., Tsukabe, R., Irokawa, Y., Funamoto, M., Suzuki, Y., Yamada, M., Shimizu, S., Katanasaka, Y., Hamabe-Horiike, T., Kawase, Y., Naruta, R., Shimizu, K., Mori, K., Hosomi, R., Komiyama, M., Hasegawa, K., & Morimoto, T. (2024). Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042344

Vancouver

Sunagawa Y, Tsukabe R, Irokawa Y, Funamoto M, Suzuki Y, Yamada M, et al. Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042344

BibTeX
@article{Sunagawa2024,
  author = {Sunagawa, Yoichi and Tsukabe, Ryosuke and Irokawa, Yudai and Funamoto, Masafumi and Suzuki, Yuto and Yamada, Miho and Shimizu, Satoshi and Katanasaka, Yasufumi and Hamabe-Horiike, Toshihide and Kawase, Yuto and Naruta, Ryuya and Shimizu, Kana and Mori, Kiyoshi and Hosomi, Ryota and Komiyama, Maki and Hasegawa, Koji and Morimoto, Tatsuya},
  title = {Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25042344}
}
Kostenlos starten →